Clicky

Daiichi Sankyo Company, Limited(DSKYF)

Description: Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic. In addition, the company offers colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus treatment; and ferric carboxymaltose and iron sucrose injections for treating anemia. Further, it provides Lulu, a combination cold remedy; Loxonin S, an antipyretic analgesic /anti-inflammatory analgesic; Transino for melasma improvement and treating against spots and freckles; Minon, a skincare product; and Breath Labo and Clean Dental oral care products, as well as Silodosin for dysuria; Gefitinib for malignant tumours; Bicalutamide for prostate cancer; and Tamoxifen, an anti-breast cancer agent. Additionally, the company offers adsorbed cell culture-derived influenza, influenza HA, measles rubella combined, and mumps vaccines. It also provides pharmaceuticals and drugs for animals, cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, and intermediates. It has collaboration with Guardant Health to develop Guardant360 CDx as a companion diagnostic for Enhertu in advanced metastatic non-small cell lung cancer. The company was founded in 1899 and is headquartered in Tokyo, Japan.


Keywords: Pharmaceutical Products Food Products Pain Diabetes Active Pharmaceutical Ingredients Alzheimer's Disease Prostate Cancer Osteoporosis Anemia Oral Care Products Hypercholesterolemia Anti Inflammatory Piperidines Levofloxacin Measles Trastuzumab Rubella Antipyretic Daiichi Sankyo Mumps Pyrazoles Bone Disorders Denosumab Dipeptidyl Peptidase 4 Inhibitor Gefitinib Melasma Silodosin Adsorbed Cell Culture Derived Influenza Advanced Metastatic Non Small Cell Lung Cancer Anti Breast Cancer Bicalutamide Canagliflozin Colesevelam Edoxaban Esomeprazole Freckles Influenza Ha Lacosamide Laninamivir Loxonin Loxoprofen Malignant Tumours Memantine Minon Mirogabalin Olmesartan Prasugrel Pravastatin Skincare Product Tamoxifen Teneligliptin

Home Page: www.daiichisankyo.com

3-5-1, Nihonbashi-honcho
Tokyo, 103-8426
Japan
Phone: 81 3 6225 1111


Officers

Name Title
Mr. Sunao Manabe D.V.M., Ph.D. Pres, Group CEO & Representative Director
Mr. Hiroyuki Okuzawa Sr. Exec. Officer, Global Head of Corp. Planning & Management Div., CFO and Director
Mr. Masahiko Ohtsuki Sr. Exec. Officer, Global Head of Digital Transformation Management Div., CIO & Director
Naoto Tsukaguchi Gen. Counsel, Corp. Officer, VP of Legal Affairs Dept. & Corp. Affairs Division
Kentaro Asakura VP of Corp. Communications Department
Ms. Marielle Cohard-Radice M.D. Global Head of Devel.
Yoshinori Kaneshima Corp. Officer and Head of Marketing Div. & Japan Bus. Unit
Akio Sakurai Corp. Officer and Head of Sales Div. & Japan Bus. Unit
Takashi Matsumoto Corp. Officer & Global Head of HR
Mr. Hideyuki Haruyama Ph.D. Corp. Adviser

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE: 62.8931
Trailing PE: 123.44
Price-to-Book MRQ: 5.8531
Price-to-Sales TTM: 0.0568
IPO Date:
Fiscal Year End: March
Full Time Employees: 16458
Back to stocks